cGAS-STING pathway activation drives inflammation, fibrosis, and podocyte injury in various kidney diseases
New research identifies a key pathway in kidney disease progression
This systematic review synthesizes preclinical data on the cGAS-STING signaling pathway's role in acute kidney injury, chronic kidney diseas…
A specific signaling pathway called cGAS-STING acts as a central hub, linking inflammation and metabolism to several types of serious kidney…
GLP-1 receptor agonists reduce apnea-hypopnea index by 15.28 events per hour in obstructive sleep apnea
GLP-1 receptor agonists show promise for obstructive sleep apnea
This network meta-analysis of 15 studies involving 1,877 participants found that GLP-1 receptor agonists significantly reduced the apnea-hyp…
New data suggests GLP-1 receptor agonists may reduce sleep apnea symptoms and improve oxygen levels in overweight or obese patients.
Evaluation of Once Weekly Subcutaneous Zenagamtide for Management of Type 2 Diabetes
New weekly injection shows promise for managing Type 2 Diabetes
Zenagamtide, a dual GLP-1 and amylin agonist, demonstrated significant HbA1c reductions in patients with type 2 diabetes over 36 weeks.
A new once-weekly injection showed significant reductions in blood sugar levels for adults living with Type 2 diabetes during a recent clini…
SGLT2 inhibitors raise hematocrit by 2.29% and hemoglobin by 0.51 g/dL in type 2 diabetes
SGLT2 Inhibitors Linked to Higher Blood Levels in Diabetes Patients
This meta-analysis of 10 studies (including RCTs and real-world data) found that SGLT2 inhibitors consistently increase hemoglobin and hemat…
New data shows SGLT2 inhibitors are linked to higher hemoglobin and hematocrit levels in adults with Type 2 Diabetes.
SGLT2 inhibitors reduce body fat without significant impacts on skeletal muscle mass in type 2 diabetes
SGLT2 Inhibitors Reduce Fat Mass in Type 2 Diabetes Patients
This network meta-analysis of 5,399 patients evaluated the effects of SGLT2 inhibitors on body composition. The study found that while SGLT2…
New analysis shows SGLT2 inhibitors consistently reduce body fat and weight in adults with type 2 diabetes without significantly reducing mu…
SGLT2 inhibitors and GLP-1 receptor agonists show similar MACE reduction in type 2 diabetes
Trial shows similar heart benefits for two diabetes medications
This systematic review and network meta-analysis compared SGLT2 inhibitors and GLP-1 receptor agonists for major adverse cardiovascular even…
Two common types of diabetes drugs both show significant reductions in major heart events for patients with a history of heart attacks.
Novel pharmacotherapies like resmetirom and GLP-1 receptor agonists offer potential concurrent hepatic and cardiovascular benefits
New Medications Show Potential to Treat Liver and Heart Disease
This systematic review examines the epidemiological links and shared pathophysiological mechanisms between metabolic dysfunction-associated …
Newer drugs like resmetirom and GLP-1 receptor agonists may offer dual benefits for patients with both liver and heart conditions.
Unified cardiometabolic disease framework links T2DM, ASCVD, HFpEF, MASLD, hypertension, and CKD via shared pathophysiology
New Framework Links Heart and Kidney Health in Diabetes
This guideline provides a narrative review of the unified cardiometabolic disease (UCD) continuum. It argues that conditions like T2DM, ASCV…
Experts suggest that diabetes, heart failure, and kidney disease may share a single underlying cause rather than being separate conditions.
Initial dual oral therapy improves HbA1c target achievement in early stage type 2 diabetes
Dual Therapy Shows Better Results for Type 2 Diabetes Control
Researchers evaluated the efficacy of initial dual oral therapy compared to monotherapy for patients with early-stage type 2 diabetes. The f…
Starting with two medications instead of one may help people with early type 2 diabetes reach their blood sugar goals more effectively.
General medical management improves medication adherence and lifestyle outcomes in older adults with type 2 diabetes
New management model improves medication use and health for seniors
This randomized controlled trial of 200 older adults with type 2 diabetes and atherosclerotic cardiovascular disease found that a general me…
A new personalized care plan helps older adults with diabetes and heart disease stay on their medications and improve their daily habits.
Finerenone reduces composite cardiovascular death and worsening heart failure events in patients with symptomatic heart failure
Finerenone Reduces Heart Failure Events in Specific Patient Groups
This narrative review evaluates finerenone for patients with symptomatic heart failure and LVEF ≥40%. It finds that finerenone reduces the c…
A new medication called finerenone may help reduce certain heart failure events for adults with specific types of heart muscle function.
SGLT2 inhibitors associated with lower all-cause mortality in heart transplant recipients with type 2 diabetes
SGLT2 inhibitors associated with lower mortality in heart transplant patients
This meta-analysis examined the impact of SGLT2 inhibitor use on outcomes for heart transplant recipients with type 2 diabetes. The authors …
New analysis suggests SGLT2 inhibitors may lower death rates for heart transplant recipients with type 2 diabetes without increasing UTI ris…